Posted on August 17, 2021
2021 NEWSLETTER Heffter supporters,   First, there have been changes at Heffter since our last newsletter. Carey Turnbull has succeeded George Greer as President. George has retired as Medical Director and is now Board Chair. Dave Nichols is Vice-President, and all three make up the Heffter Executive Committee. Our new Director of Research is Steven Grant, PhD, who joins us after 25 years at the National Institute on Drug Abuse, where he was Chief of

Winter 2018/19 Newsletter

Posted on January 28, 2019
Dear Friends and Supporters, The Heffter Research Institute is celebrating 25 years of progress this year, having been incorporated in 1993!  We are hearing from more and more scientists who are becoming interested in the therapeutic potential of psilocybin-assisted therapy, and 2018 has been an exciting year of expansion, with new projects starting and in development. New Studies We’re supporting an important new study that will be starting soon at the University of Wisconsin investigating psilocybin

Newsletter Spring 2018

Posted on April 11, 2018
2018 is bringing new opportunities for Heffter’s research mission.  As the FDA Phase 3 work on psilocybin-assisted therapy for depression proceeds at the Usona Institute, Heffter is moving forward with its agenda to support research to test psilocybin’s healing potential for other conditions, such as addictions, eating disorders, and Alzheimer’s disease. The work ahead is only possible because of the decades of work by scientists and supporters alike who are dedicated to psychedelic research and have been working together to
“JUDY WOODRUFF: Now: why some psychiatrists and researchers are giving psychedelic drugs a second look as a possible way of treating depression and some mental illnesses. The idea had been shunned for years, but now some say a time for larger trials with the drugs is due. Miles O’Brien has the story for our weekly segment on the Leading Edge of science.” Read and listen to the full story on PBS Newshour here

Heffter Research Winter 2016 Newsletter

Posted on December 16, 2016
2016 has been a watershed year for the Heffter Research Institute and its programs! We believe that our work is contributing to what we hope will be a paradigm shift in the way that many psychiatric and addictive disorders are treated. We hope you enjoy reading about all of the great things we have accomplished this past year. Johns Hopkins and NYU Studies of Psilocybin for Anxiety and Depression in Cancer Patients Our big news

News Coverage for Recent Psilocybin Studies

Posted on December 3, 2016
Heffter Research Institute is proud to have supported new psilocybin studies published December 1 in The Journal of Psychopharmacology reporting the effectiveness of using psilocybin to reduce depression, anxiety and existential distress in cancer patients. Below is a round-up of articles discussing the recent findings of the NYU School of Medicine and Johns Hopkins University studies.   Hallucinogen Eases Depression in Cancer Patients, Studies Find – The New York Times Magic Mushroom Ingredient Psilocybin Can
“On a summer morning in 2013, Octavian Mihai entered a softly lit room furnished with a small statue of Buddha, a box of tissues and a single red rose. From an earthenware chalice, he swallowed a capsule of psilocybin, an ingredient found in hallucinogenic mushrooms. Then he put on an eye mask and headphones and lay down on a couch. Soon, images flew by like shooting stars: a spinning world that looked like a blue-green
“A single dose of psilocybin, the long-banned active compound in “magic mushrooms,” significantly reduced anxiety, depression and the fear of death among cancer patients for months at a time, according to two studies published Thursday. Eighty people in separate clinical trials at Johns Hopkins University School of Medicine and New York University Langone Medical Center were given psilocybin under close supervision. The vast majority experienced an increase in optimism, a feeling of connection with other
“The doom hung like an anvil over her head. In 2012, a few years after Carol Vincent was diagnosed with non-Hodgkin lymphoma, she was waiting to see whether her cancer would progress enough to require chemotherapy or radiation. The disease had already done a number on her, inflating lymph nodes on her chin, collar bones, and groin. She battled her symptoms while running her own marketing business. To top it all off, she was going
“Researchers at the Johns Hopkins University School of Medicine have found that a psychedelic drug can significantly reduce anxiety, depression and other emotional distress in cancer patients. The patients experienced almost immediate relief, which lasted for months, after taking psilocybin, the active hallucinogenic ingredient in “magic mushrooms,” the researchers reported. A separate study by researchers at NYU Langone Medical Center found the same effect.” Read the full Baltimore Sun article by Andrea K. McDaniels here